The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis - 09/08/11
Doi : 10.1016/j.jaad.2005.10.006
Alan Menter, MD a, b, ⁎ 
, Jennifer C. Cather, MD a, Diane Baker, MD c, Harold F. Farber, MD d, Mark Lebwohl, MD e, Mohamed Darif, PhD f
, Jennifer C. Cather, MD a, Diane Baker, MD c, Harold F. Farber, MD d, Mark Lebwohl, MD e, Mohamed Darif, PhD f a From the Baylor University Medical Center, Dallas, Texas
b UT Southwestern Medical School, Dallas, Texas
c Allergy, Asthma, and Dermatology Research Center, Lake Oswego, Oregon
d Harold F. Farber, MD, PC, and Associates, Clinical Research, Philadelphia, Pennsylvania
e Mt Sinai School of Medicine, New York, New York
f Biogen Idec Inc, San Diego, California
Reprint requests: Alan Menter, MD, 5310 Harvest Hill Rd, Suite 260, Dallas, TX 75230.Dallas, Texas; Lake Oswego, Oregon; Philadelphia, Pennsylvania; New York, New York; and San Diego, California
Abstract |
Among patients with psoriasis who did not achieve Psoriasis Area and Severity Index 50 during the first course of alefacept therapy, 53% achieved Psoriasis Area and Severity Index 50 during the second course (odds ratio [95% confidence interval] vs placebo 2.30 [1.26-4.19]). Alefacept provided incremental efficacy over 5 successive 12-week treatment courses.
Le texte complet de cet article est disponible en PDF.Abbreviations used : IM, IV, PASI, PGA
Plan
| Supported by Biogen Idec, Cambridge, Massachusetts. |
|
| Disclosure: Dr Menter has received research support and/or is a consultant and/or speaker for Abbott Laboratories, Allergan Inc, Allermed, Amgen Inc, Astralis Inc, Berlex Inc, Biogen Idec Inc, Centocor Inc, Collagenex Pharmaceuticals, Connetics Corp, Dermik Laboratories, Doak Dermatologics, Dow, Ferndale Laboratories Inc, Fujisawa Healthcare Inc, Galderma, Genentech Inc, GlaxoSmithKline, Ligand Pharmaceuticals, Medicis, MedImmune Inc, Novartis Pharmaceuticals, Otsuka Pharmaceutical Inc, Serono, Synta Pharma, Thermosurgery, 3M Pharmaceuticals, and XOMA. Dr Cather has received research support and/or is a consultant and/or speaker for Abbott, Allergan, Amgen, Astralis, Berlex, Biogen Idec, Bradley Pharmaceuticals, Brymill Cryogenics, Centocor, Collagenex, Connetics, Corixa Corp, Dermik, Doak, Ferndale, Fujisawa, Galderma, Genentech, GlaxoSmithKline, Ligand, Medicis, MedImmune, Novartis, Otsuka, Protein Design Labs, Sereno, Synta, and 3M. Dr Baker has received research support and/or is a consultant and/or speaker for Abbott, Amgen, Biogen Idec, Centocor, CombinatoRx Inc, Galderma, Genentech, GlaxoSmithKline, Serono, and Synta. Dr Farber has received research support and/or is a consultant and/or speaker for Biogen Idec and other pharmaceutical companies involved in the development of therapies for the treatment of moderate to severe chronic plaque psoriasis. Dr Lebwohl has received research support and/or is a consultant and/or speaker for Abbott, Amgen, Biogen Idec, Centocor, Connetics, and Genentech. Dr Darif is an employee of Biogen Idec. |
© 2006
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 54 - N° 1
P. 61-63 - janvier 2006 Retour au numéro
Article précédent
- Subcutaneous sarcoidosis: Is it a specific subset of cutaneous sarcoidosis frequently associated with systemic disease?
- Iftikhar Ahmed, Sujata R. Harshad
- Availability of Journal Back Issues
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?